CJBH492A12101: A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non-Hodgkin´s Lymphoma (NHL)
Principal investigator: Vesa Lindström
HUS Helsinki University Hospital, Comprehensive Cancer Center